アムロジピンとオルメサルタンの世界市場規模：製品別、用途別、地域範囲別、予測

アムロジピンとオルメサルタンの市場規模と予測

アムロジピンとオルメサルタンの市場規模は、2024年に5億9,795万米ドルと評価され、2024～2032年にかけてCAGR 4.10%で成長し、2032年には8億2,465万米ドルに達すると予測されます。

アムロジピンとオルメサルタンは、主に高血圧（高脂血症）の治療に用いられる薬剤の組み合わせです。カルシウム拮抗薬であるアムロジピンは血管を弛緩させて血流を改善し、アンジオテンシンII受容体拮抗薬であるオルメサルタンは血管の収縮を防ぐのに役立ちます。

この組み合わせは、効果的なコントロールのために複数の治療が必要な患者の血圧値管理に広く応用されています。

今後、世界の心血管疾患の罹患率の増加に伴い、アムロジピンとオルメサルタンの需要は、製剤の進歩や、患者の予後を改善するための併用療法が重視されるようになることで、増加すると予想されます。

アムロジピンとオルメサルタンの世界市場力学

世界のアムロジピンとオルメサルタン市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

高血圧有病率の上昇：世界保健機関（WHO）によると、世界で30～79歳の成人12億8,000万人が高血圧であると推定され、今後も増加が見込まれます。このような患者数の増加が、アムロジピンやオルメサルタンのような効果的な降圧薬の需要を牽引しています。

併用療法の嗜好：医療従事者がより少ない副作用でより良好な血圧コントロールを達成することを目指していることから、高血圧治療における併用療法の動向は勢いを増しています。アムロジピンとオルメサルタンの相乗効果により、臨床医と患者にとって好ましい選択肢となっています。

高齢者の増加：国連によれば、世界の高齢者は2050年までに15億人に達すると予測されています。この層は高血圧のリスクが高いため、高齢者に特化した降圧薬の市場が拡大しています。

薬剤製剤の進歩：合剤などのドラッグデリバリーシステムの革新は、患者のコンプライアンスと治療効果を高めています。これらの進歩は投与を容易にし、患者の転帰を改善するため、アムロジピンとオルメサルタン市場の拡大を支えています。

主要課題

ジェネリック競合：アムロジピンとオルメサルタンのジェネリック医薬品の参入は、市場の成長にとって大きな課題となります。低価格のジェネリック医薬品は、ブランド製品の価格低下や利益率の低下を招く可能性があります。

副作用：めまい、むくみ、胃腸障害など、アムロジピンとオルメサルタンに関連する副作用の可能性は、一部の患者が配合された治療の継続を躊躇し、市場の需要に影響を与える可能性があります。

規制上のハードル：新剤形や併用療法の承認プロセスは長期化・複雑化する可能性があり、革新的な製品の市場導入が遅れ、成長機会が制限されます。

経済的要因：経済不安やヘルスケア予算の制約が薬価・償還施策に影響を及ぼし、特に中低所得国の患者にとって必要不可欠な医薬品へのアクセスが制限される可能性があります。

主要動向

個別化医療の重視：患者一人ひとりの特性を考慮した個別化治療計画が重視されるようになってきており、その結果、より効果的な高血圧管理が可能になり、アムロジピンやオルメサルタンなどの個別化治療の使用が増加する可能性があります。

デジタルヘルスの統合：モバイルヘルスアプリケーションや遠隔医療などのデジタルヘルス技術の台頭は、患者のモニタリングや服薬アドヒアランスに変革をもたらし、降圧療法の採用にプラスの影響を与える可能性があります。

意識向上と教育：高血圧とそのリスクに関する認識を高めることを目的とした取り組みにより、より多くの患者が治療を受けるようになっています。ヘルスケアプロバイダや組織による教育プログラムは、服薬アドヒアランスの重要性を推進しています。

医薬品業務の持続可能性：医薬品産業では、環境への影響を低減するための世界の取り組みと歩調を合わせ、医薬品の製造と包装においてよりサステイナブルプラクティスへのシフトが見られ、今後の市場力学に影響を与える可能性があります。

目次

第1章 アムロジピンとオルメサルタンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 アムロジピンとオルメサルタンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 アムロジピンとオルメサルタンの世界市場：製品別

• 概要
• 5/20mg錠
• /20mg錠
• 5/40mg錠
• /40mg錠

第6章 アムロジピンとオルメサルタンの世界市場：用途別

• 概要
• 病院
• ドラッグストア

第7章 アムロジピンとオルメサルタンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のアムロジピンとオルメサルタン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Glenmark Pharmaceuticals
• Teva
• Torrent Pharmaceuticals
• Daiichi Sankyo
• Accord Healthcare
• Macleods Pharmaceuticals
• Alembic Pharmaceuticals

第10章 付録

• 関連調査

Amlodipine And Olmesartan Market Size And Forecast

Amlodipine And Olmesartan Market size was valued at USD 597.95 Million in 2024 and is projected to reach USD 824.65 Million by 2032, growing at a CAGR of 4.10% from 2024 to 2032.

Amlodipine and Olmesartan are a combination of medications used primarily to treat hypertension (high blood pressure). Amlodipine, a calcium channel blocker, relaxes blood vessels, improving blood flow, while Olmesartan, an angiotensin II receptor blocker, helps prevent blood vessel constriction.

This combination is widely applied to manage blood pressure levels in patients who require multiple therapies for effective control.

In the future, with the growing global incidence of cardiovascular diseases, the demand for Amlodipine and Olmesartan is expected to rise, driven by advancements in drug formulations and increased emphasis on combination therapies for better patient outcomes.

Global Amlodipine And Olmesartan Market Dynamics

The key market dynamics that are shaping the global Amlodipine And Olmesartan Market include:

Key Market Drivers:

Rising Hypertension Prevalence: According to the World Health Organization (WHO), an estimated 1.28 billion adults aged 30-79 worldwide have hypertension, which is expected to increase. This growing patient population drives the demand for effective antihypertensive medications like Amlodipine and Olmesartan.

Combination Therapy Preference: The trend toward combination therapies in hypertension treatment is gaining momentum as healthcare providers aim to achieve better blood pressure control with fewer side effects. The synergistic effect of Amlodipine and Olmesartan makes it a preferred choice for clinicians and patients.

Increasing Geriatric Population: The global geriatric population is projected to reach 1.5 billion by 2050, according to the United Nations. This demographic is at a higher risk for hypertension, resulting in a growing market for antihypertensive medications that cater specifically to older adults.

Advancements in Drug Formulations: Innovations in drug delivery systems, such as fixed-dose combinations, enhance patient compliance and treatment efficacy. These advancements support the expansion of the Amlodipine And Olmesartan Market as they facilitate easier administration and improve patient outcomes.

Key Challenges:

Generic Competition: The entry of generic versions of Amlodipine and Olmesartan poses a significant challenge to market growth. Lower-priced alternatives can lead to price erosion and reduced profit margins for branded products.

Adverse Drug Reactions: Potential side effects associated with Amlodipine and Olmesartan, such as dizziness, swelling, or gastrointestinal issues, may deter some patients from continuing their prescribed treatment, impacting market demand.

Regulatory Hurdles: The approval process for new formulations and combination therapies can be lengthy and complex, delaying the introduction of innovative products in the market and limiting growth opportunities.

Economic Factors: Economic instability and healthcare budget constraints can affect drug pricing and reimbursement policies, limiting access to essential medications for patients, particularly in low- and middle-income countries.

Key Trends:

Focus on Personalized Medicine: There is a growing emphasis on personalized treatment plans that take into account individual patient characteristics, which can lead to more effective hypertension management and increased use of tailored therapies, including Amlodipine and Olmesartan.

Digital Health Integration: The rise of digital health technologies, such as mobile health applications and telemedicine, is transforming patient monitoring and medication adherence, which may positively influence the adoption of antihypertensive therapies.

Increased Awareness and Education: Initiatives aimed at raising awareness about hypertension and its risks are encouraging more individuals to seek treatment. Educational programs from healthcare providers and organizations are promoting the importance of medication adherence.

Sustainability in Pharmaceutical Practices: The industry is witnessing a shift toward more sustainable practices in drug manufacturing and packaging, aligning with global efforts to reduce environmental impact, which may influence future market dynamics.

Global Amlodipine And Olmesartan Market Regional Analysis

Here is a more detailed regional analysis of the global Amlodipine And Olmesartan Market:

North America:

North America is the dominant region in the Amlodipine And Olmesartan Market, primarily driven by a robust healthcare infrastructure, high prevalence of hypertension, and increased awareness of cardiovascular diseases. The United States and Canada contribute significantly to market growth due to the presence of well-established pharmaceutical companies and advanced research and development facilities. According to the Centers for Disease Control and Prevention (CDC), approximately 47% of adults in the U.S. have hypertension, underscoring the high demand for effective antihypertensive medications like Amlodipine and Olmesartan.

Additionally, the region benefits from strong regulatory support and favorable reimbursement policies, which encourage the adoption of innovative healthcare solutions. The American Heart Association has reported a growing emphasis on managing hypertension, resulting in a surge in prescriptions for Amlodipine and Olmesartan. This trend is bolstered by increasing public health initiatives aimed at reducing cardiovascular risks, further solidifying North America's position as a leader in the market.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for Amlodipine and Olmesartan, driven by rapid urbanization, rising disposable incomes, and increasing awareness of health and wellness among consumers. Countries like India and China are experiencing significant growth due to the rising prevalence of lifestyle-related diseases, including hypertension. The World Health Organization (WHO) estimates that hypertension affects about 30% of the adult population in these countries, highlighting a vast potential customer base for these antihypertensive medications.

Moreover, the growing investment in healthcare infrastructure and an increasing number of healthcare facilities are facilitating the expansion of the Amlodipine And Olmesartan Market in the region. Governments in Asia Pacific are also implementing various public health initiatives to promote hypertension awareness and improve access to healthcare services. As a result, the demand for effective antihypertensive treatments is expected to surge, driving market growth in this dynamic region.

Global Amlodipine And Olmesartan Market: Segmentation Analysis

The Global Amlodipine And Olmesartan Market is Segmented on the basis of Product, Application, and Geography.

Amlodipine And Olmesartan Market, By Product

5/20 mg Tablets

10/20 mg Tablets

5/40 mg Tablets

10/40 mg Tablets

Based on Product, the Global Amlodipine And Olmesartan Market is segmented into 5/20 mg Tablets, 10/20 mg Tablets, 5/40 mg Tablets, and 10/40 mg Tablets. The 5/20 mg tablets segment is dominating due to their widespread acceptance among healthcare providers and patients, as they offer a balanced dosage for managing mild to moderate hypertension. However, the 10/40 mg tablets segment is the fastest-growing segment, driven by an increasing patient population requiring higher doses for effective blood pressure control.

Amlodipine And Olmesartan Market, By Application

• Hospitals
• Drug Stores

Based on Application, the Global Amlodipine And Olmesartan Market is segmented into Hospitals, and Drug Stores. The Hospitals segment is dominating due to their comprehensive patient management capabilities and the availability of specialized medical personnel to prescribe and administer these medications. Hospitals play a crucial role in the initial treatment and stabilization of patients with hypertension, leading to higher medication usage. However, the drug stores segment is the fastest-growing segment, driven by increasing patient self-management of chronic conditions and a growing preference for over-the-counter access to antihypertensive medications.

Key Players

The "Global Amlodipine And Olmesartan Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market Glenmark Pharmaceuticals, Teva, Torrent Pharmaceuticals, Daiichi Sankyo, Accord Healthcare, Macleods Pharmaceuticals, Alembic Pharmaceuticals.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Amlodipine And Olmesartan Market: Recent Developments
• In May 2024 Aurobindo Pharma Limited announced the receipt of final approval from the U.S. Food and Drug Administration (FDA) for its Amlodipine and Olmesartan Medoxomil Tablets in multiple dosages (5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg). This product is now recognized as bioequivalent to Daiichi Sankyo's Azor(R) and is expected to cater to the significant market, which had an estimated size of $255.8 million for the year ending March 2017.
• In August 2024 Hikma Pharmaceuticals successfully launched its generic version of Amlodipine and Olmesartan in the U.S. market. This strategic move allows Hikma to expand its generic product line, leveraging its existing distribution channels and manufacturing capabilities.
• In July 2024 Cipla Limited revealed plans to expand its marketing efforts for Amlodipine and Olmesartan in emerging markets. The company aims to increase access to these essential medications in regions with high hypertension prevalence. Cipla's initiative includes collaborations with local healthcare providers to ensure that patients can easily access these treatments, enhancing health outcomes in underserved populations.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL AMLODIPINE AND OLMESARTAN MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL AMLODIPINE AND OLMESARTAN MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL AMLODIPINE AND OLMESARTAN MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 5/20 mg Tablets
• 5.310/20 mg Tablets
• 5.4 5/40 mg Tablets
• 5.510/40 mg Tablets

6 GLOBAL AMLODIPINE AND OLMESARTAN MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Drug Stores

7 GLOBAL AMLODIPINE AND OLMESARTAN MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL AMLODIPINE AND OLMESARTAN MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Glenmark Pharmaceuticals
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Teva
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Torrent Pharmaceuticals
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Daiichi Sankyo
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Accord Healthcare
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Macleods Pharmaceuticals
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Alembic Pharmaceuticals
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments

10 Appendix

• 10.1 Related Research